Back to today’s briefing

Story perspectives

Biotech Revolution: Lilly Acquires Verve, AI Innovations Unveiled

6/22/2025

50 5

Summary

Story summary

At the BIO 2025 conference, excitement fills the air as Lilly's acquisition of Verve Therapeutics sparks vital discussions about the future of industry-backed therapeutics. Meanwhile, Xaira Therapeutics unveils a groundbreaking Perturb-seq dataset, and AlphaDesign showcases an innovative AI framework for custom protein design, underscoring the powerful synergy between AI and precision medicine in biotech.

1 of 1

Story summary

At the BIO 2025 conference, excitement fills the air as Lilly's acquisition of Verve Therapeutics sparks vital discussions about the future of industry-backed therapeutics. Meanwhile, Xaira Therapeutics unveils a groundbreaking Perturb-seq dataset, and AlphaDesign showcases an innovative AI framework for custom protein design, underscoring the powerful synergy between AI and precision medicine in biotech.